Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alogliptin/pioglitazone - Takeda

Drug Profile

Alogliptin/pioglitazone - Takeda

Alternative Names: Alogliptin/Actos; Incresync; Liovel HD; Liovel LD; NesinaAct; Oseni; Pioglitazone/alogliptin; SYR 322/pioglitazone; SYR-322-4833 BL

Latest Information Update: 22 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Piperidines; Pyrimidinones; Small molecules; Thiazolidinediones
  • Mechanism of Action CD26 antigen inhibitors; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 11 Jul 2018 Takeda completes a phase I trial in Healthy volunteers in Russia (PO) (NCT03501277)
  • 24 Jun 2018 Biomarkers information updated
  • 25 May 2018 Takeda initiates a phase I trial in Healthy volunteers in Russia (PO) (NCT03501277)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top